Vimarsana
Biggest News Aggregation in the World

Page 4 - Silverstein Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Silverstein Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Silverstein Foundation Today - Breaking & Trending Today

Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson's Disease Therapeutics Conference | Region - Vimarsana News

Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson's Disease Therapeutics Conference | Region

SAN CARLOS, Calif.--(BUSINESS WIRE)--Oct 10, 2023--

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease - Vimarsana News

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical developmentBETHESDA, Md., Oct. 04, 2023 -- Gain Therapeutics, Inc. , a...

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia - Vimarsana News

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

                First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 ...

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update - Vimarsana News

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to... | May 12, 2023

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease - Vimarsana News

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease

BETHESDA, Md., May 03, 2023 -- Gain Therapeutics, Inc. , a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the... | May 3, 2023